UBS Maintains Intra-Cellular Therapies(ITCI.US) With Hold Rating, Raises Target Price to $87
Express News | Intra-Cellular Therapies Inc : UBS Raises Target Price to $87 From $79
Intra-Cellular Therapies to Participate in Three Upcoming Investor Conferences
US Manufacturing Index Rises To 43, Highest Since 2020
Intra-Cellular Therapies Insider Sold Shares Worth $3,692,100, According to a Recent SEC Filing
Intra-Cellular Therapies(ITCI.US) Officer Sells US$3.69 Million in Common Stock
$Intra-Cellular Therapies(ITCI.US)$ Officer Halstead Michael sold 41,583 shares of common stock on Nov 12, 13, 2024 at an average price of $88.79 for a total value of $3.69 million.Source: